VolitionRX Limited (VNRX)

VolitionRx Announces Pricing of $4.6 Million Public OfferingJune 7, 2026 6:30 PM
PR Newswire (US) $4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the pricing of its previously announced public offering of 2,960,000 shares of common stock, and warrants to purchase up to an aggregate of 1,480,000 shares of common stock, at a combined public offering price of $1.55 per share and accompanying half warrant. Each warrant will have an exercise price of $1.55 per share, will be exercisable immediately upon issuance, and will expire five years after the date of issuance. The offering included participation from both new and existing investors.Maxim Group LLC is acting as the sole placement agent in connection with the offering.The gross proceeds for the offering are expected to be approximately $4.6 million before deducting placement agent fees and other offering expenses and excluding the proceeds from the exercise of any warrants. The additional gross proceeds to the Company from the exercise of the warrants, if fully-exercised on a cash basis, will be approximately $2.3 million.  However, no assurance can be given that any of the warrants will be exercised.The offering is expected to close on June 9, 2026, subject to the satisfaction of customary closing conditions.The securities in the offering are being offered by Volition pursuant to an effective shelf registration statement on Form S-3 (File No. 333-283088), initially filed with the U.S. Securities and Exchange Commission (the "SEC") on November 8, 2024, as amended, and declared effective on April 18, 2025. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying base prospectus relating to and describing the terms of the public offering were filed with the SEC and are available on the SEC's website at www.sec.gov. A final prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, and when filed, the final prospectus supplement and accompanying base prospectus, relating to the public offering may also be obtained by contacting Maxim Group LLC, at 300 Park Avenue, 16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About VolitionVolition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current belief and expectations of management and relate to, among other topics, statements regarding the expected completion, timing and gross proceeds of the offering. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward- looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the proposed public offering, risks disclosed in the section titled "Risk Factors" included in the preliminary prospectus supplement filed with the SEC on June 5, 2026, and risks disclosed in other documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. View original content:https://www.prnewswire.com/news-releases/volitionrx-announces-pricing-of-4-6-million-public-offering-302793460.htmlSOURCE VolitionRx Limited Original: VolitionRx Announces Pricing of $4.6 Million Public Offering

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment MonitoringJune 3, 2026 8:12 AM
PR Newswire (US) Seeks Strategic Partners to Deploy Nu.Q® Platform in Outbreak ZonesHENDERSON, Nev., June 3, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has expanded its robust intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q® technology in triaging and monitoring patients who are suspected of having contracted the Ebola virus.Dr. Jake Micallef, Chief Scientific Officer, Volition commented:"This filing yet again shows the breadth of utility of our technology:  it claims  the potential use of Volition's existing Nu.Q® NETs test for Ebola. The Nu.Q® NETs test quantifies circulating nucleosomes and Neutrophil Extracellular Traps (NETs) as early indicators of hyper-inflammation leading to septic shock and early mortality.  "Our existing patented product portfolio includes the CE-Marked automated Nu.Q® NETs assay for use in centralized laboratories, in addition to the recently announced capillary blood finger-prick lateral flow detection (LFT). The LFT could offer an unprecedented bedside triage solution for severe filovirus outbreaks, creating a compelling pathway into underserved,  resource constrained countries, where laboratory infrastructure may be weak or non-existent."While existing Ebola diagnostics focus entirely on identifying the presence of the virus, Volition's technology focuses on the host's dysregulated immune response. The Nu.Q® NETs test measures H3.1 nucleosomes, which serve as an independent predictor of organ failure and mortality in patients with sepsis and COVID-19. Similarly, identification of elevated NETs levels prior to clinical deterioration may help field medics prevent disease spread and provide earlier, more effective treatment for Ebola-infected patients."Meeting the Critical Need in Ebola Ebola is a rare but severe illness in humans, with an average case fatality rate around 50%1 .  The disease is characterized by a low white cell count, disseminated intravascular coagulation, immunosuppression and septic shock.The ongoing Ebola outbreaks across Sub-Saharan Africa highlight a persistent medical challenge: because initial symptoms are non-specific, clinicians in remote field facilities cannot easily identify infected patients sufficiently early to prevent disease spread and for early treatment. A Call for Strategic PartnershipsWith its core laboratory automated assays already CE-Marked and in use in a number of clinical programs, Volition is looking to translate this technology into immediate field application. The company is actively inviting global health organizations, pharmaceutical developers, non-governmental organizations (NGOs), and distribution partners to collaborate on field trials, manufacturing scale-up, and potential deployment of its LFT prototypes in outbreak zones.Mr. Remi Rabeuf, VP of Corporate Alliances and Strategic Partnerships, Volition said:"Our Nu.Q® technology has demonstrated its potential to improve sepsis care in advanced Western settings and with this new patent filing and our successful finger-prick LFT prototype, we now hope to take this prognostic power into most low- and middle-income country healthcare settings."We are seeking the right institutional and commercial partners to help us get this low-cost, life-saving triage tool into the hands of frontline healthcare workers fighting Ebola."For partnership, licensing, or media inquiries, contact our alliance team directly at mediarelations@volition.com.World Health Organization (Ebola Disease Factsheet).About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements or other arrangements with third parties for its products, and Volition's expectations regarding the terms of such agreements or arrangements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nu.Q®, rNuq™, Nucleosomics™, Capture-PCR™ and Capture-Seq™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. View original content:https://www.prnewswire.com/news-releases/volitionrx-files-new-patent-protecting-its-nuq-nets-test-for-ebola-triage-and-treatment-monitoring-302790033.htmlSOURCE VolitionRx Limited Original: VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable MarketsMay 27, 2026 8:17 AM
PR Newswire (US) Update Highlights 300% Q1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, and Active Licensing Discussions with More Than a Dozen Global Diagnostic LeadersHENDERSON, Nev., May 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provided a comprehensive corporate update highlighting the significant clinical and commercial progress achieved over recent months.   Key Highlights:First Quarter Revenue Growth: Reported $1M of revenue in the first quarter of 2026, representing a 300% increase year-over-year.Feline Lymphoma Manuscript Submission: Formally submitted the clinical manuscript for the Nu.Q® Vet cancer test in cats; $5 million milestone payment anticipated subsequent to publication.Global Licensing Momentum: Company confirms active discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies, including for technical evaluations.Capture-Seq™ Platform: Paper submitted for peer review; validation cohort detected over 95% of Stage I and II cancers2; underscores a $23 billion1 annualized opportunity in cancer detection.Sepsis & NETosis Validation: Inclusion of the Nu.Q® NETs assay in the $7.3 million government-backed DETECSEPS program in France.Breakthrough Finger-Prick Detection of Nucleosomes: Expanding global market potential for sepsis testing using lateral flow.European Lung Cancer Reimbursement: Formal reimbursement submission in France remains on schedule, with routine clinical use expected by end of 2026.Capture-Seq™ Breakthrough in Cancer Detection.We were delighted to submit for peer review a manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy". This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.We also announced over 95% sensitivity for stage I & II cancers with 95% specificity in a blinded validation cohort2. For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need.This scientific breakthrough has generated a lot of interest with potential licensing partners. We believe that this technology could, with further development, become very widely used and we are actively advancing structured discussions with potential commercial partners to accelerate the integration and launch of this technology as soon as possible. We are delighted to have grown the commercial interest in the first quarter, with an increase in discussions, including technical evaluations.We believe MCED represents a significant commercial opportunity with Total Addressable Markets on an annualized basis of approximately $23 billion  and a potential additional $13 billion should it also prove useful in the detection of Minimal Residual Disease1Companion Animal Health: Nu.Q® Vet Feline MilestoneWe announced the submission of a clinical manuscript3 reporting the high accuracy of our Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species4. At 97% specificity the assay detected 86% of feline lymphomas3 . This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine.This represents a tremendous commercial opportunity for Volition:The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment.We will also generate ongoing revenue,  in this large and growing market where our technology meets an unmet need.The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space1.Sepsis & NETosis ValidationThe inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed (~$7.3 million) program in France remains on track to start in the third quarter of 2026. The DETECSEPS program provides an opportunity to receive individualized or personalized care, adjusted to the risk of deterioration and progression to sepsis.We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic5, we demonstrated Nu.Q® NETs' potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,6 which affects about 1% of the world's population7. Both use cases have the potential to be large markets.Breakthrough Finger-Prick Detection of NucleosomesWe also announced a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using our lateral flow prototype. This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing.With recent estimates indicating approximately 166 million cases of sepsis worldwide the addressable market is huge. All-cause sepsis related deaths in 2021 represented 31.5%8 of total global deaths, with the highest burden of mortality in lower-middle-income countries.Lung Cancer Reimbursement SubmissionIn the fourth quarter of 2025, we received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer and in January were delighted to announce that preparation of the reimbursement submission is underway, actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system. Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the end of 2026.  Our Goal and VisionWe have developed a truly remarkable, versatile platform and have further strengthened our Intellectual Property portfolio as we continue our licensing discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies. Our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations. Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress.Our vision is for our technologies to be incorporated into tests that will be used first by millions,  and ultimately, hundreds of millions of people and animals a year, with our platform licensed to a range of large diagnostic and liquid biopsy companies (and governments) worldwide. Combining our groundbreaking technology with their installed base of laboratories, analyzer machines and sales forces around the world will achieve the optimal outcome for us – large companies have the resources to realize the opportunities better than Volition.The Total Addressable Markets1 (TAMs) for our technologies, on an annualized basis, are multi-billion-dollar opportunities, not only for Volition, but for our licensing partners. Volition has made strong progress, both clinically and commercially, and our technology is now poised to be used very widely in a broad range of clinical utilities.Summary of Addressable Markets (TAM)1PillarEstimated Annualized TAMStatusCapture-Seq™ Cancer Detection$23 BillionManuscript in Peer ReviewNu.Q® NETs (Sepsis/Chronic)$3.8 BillionCE-Marked / Clinically AvailableNu.Q® Vet (Canine/Feline)$1.0+ BillionCanine is Commercially AvailableManuscript in Peer ReviewData on File: Volition TAM ModelData on File: VolitionCanale, Annalisa et al. Evaluation of Circulating H3.1 Nucleosomes in the Plasma of Cats with Intermediate-large Cell Lymphoma, 2026, Available at SSRN: http://dx.doi.org/10.2139/ssrn.6657098Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.Navarro, Sergio M. et al. . Circulating Nucleosomes Are Elevated In Trauma Patients With Venous Thromboembolism: A Prospective Case-Cohort Study. Shock, 2026.DOI: 10.1097/SHK.0000000000002807Styliani Theohar et al. Plasma H3.1-Nucleosomes to Classify Severity and Surrogate Response to Treatment in Hidradenitis Suppurativa : A Cohort Study. medRxiv https://doi.org/10.64898/2026.01.13.26343988Bouazzi D, Nielsen SM, Hagan PG, et al. JAMA Dermatol. 2025. https://doi.org/10.1001/jamadermatol.2025.2373Gray, Authia P et al.  Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. doi: 10.1016/s2214-109x(25)00356-0About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.rNuq™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.Video - https://www.youtube.com/watch?v=1IDfE7zKHG4 View original content to download multimedia:https://www.prnewswire.com/news-releases/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution-across-27-billion-total-addressable-markets-302782965.htmlSOURCE VolitionRx Limited Original: VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

$VNRX $2.715 +9.04% VolitionRX: Q1 Earnings Snapshot #MarketScreener https://www.marketscreener.com/news/volitionrx-q1-earnings-snapshot-ce7f5bd2d88df723?utm_source=twitter&utm_medium=social&utm_campaign=share

$VNRX Q1 '26 Earnings Results & Recap

VolitionRX Ltd reported total revenues of $985,076 for Q1 2026, a significant increase from $246,385 in Q1 2025, driven by product sales. Net loss increased to $6.7M from $5.5M year-over-year. Cash and cash equivalents reached $3.1M.
Bullish

VolitionRX Ltd's total revenues significantly increased to $985,076 for the three months ended March 31, 2026, from $246,385 in the prior year period. This growth was primarily driven by product sales of the Nu.Q Vet Cancer Test and Nu.Q Discover kits.


VolitionRX Ltd has expanded its market reach through strategic partnerships with diagnostic and liquid biopsy companies, including Werfen, Hologic, and Antech. The Nu.Q Vet Cancer Test is now available in over twenty countries, demonstrating market penetration.


VolitionRX Ltd successfully raised capital, with net cash provided by financing activities increasing to $7.6M for Q1 2026 from $3.7M in Q1 2025. Cash and cash equivalents rose to $3.1M by March 31, 2026, from $1.1M at year-end 2025.

Bearish

VolitionRX Ltd incurred a net loss of $6.7M and used $5.3M in cash from operating activities for the three months ended March 31, 2026. Management identified substantial doubt about VolitionRX Ltd's ability to continue as a going concern without further financing.


Management concluded that VolitionRX Ltd's disclosure controls and procedures were not effective as of March 31, 2026. This was due to identified material weaknesses in internal control over financial reporting, including insufficient written documentation.


Total operating expenses for VolitionRX Ltd increased to $6.3M for Q1 2026 from $5.8M in Q1 2025. Other expenses increased to $1.4M from $0.0 million, driven by non-cash amortization of debt discount and loss on debt extinguishment.

$VNRX Event: VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call
Date: Friday, May 15, 2026
Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13760656

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business UpdateMay 14, 2026 4:10 PM
PR Newswire (US) Conference call to discuss financial and operational results scheduled for 
Friday, May 15 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., May 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter 2026. Volition management will host a conference call tomorrow, May 15 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.Cameron Reynolds, President and Group Chief Executive Officer, said:"We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end."We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform."We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives."We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic[1], we demonstrated Nu.Q® NETs' potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,[2] which affects about 1% of the world's population. Both use cases have the potential to be large markets."We are currently in discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue."We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations."Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress."Financial HighlightsRevenue for the first quarter was approximately $1.0 million, compared to $0.2 million for the same period in 2025.Operating loss was down 3% for the quarter versus the comparable quarter in 2025.Net cash used in operating activities was $5.3 million.Receipts in the quarter included:$5.4 million in net proceeds from equity sales through our at-the-market facility,$1.9 million in net proceeds from issuance of a convertible note and warrant, and$1 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.Event: VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call
Date: Friday, May 15, 2026
Time: 8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13760656Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter of 2026, subsequent events and upcoming milestones.A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until May 29, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13760656.Navarro, Sergio M. et al, Circulating Nucleosomes Are Elevated In Trauma Patients With Venous Thromboembolism: A Prospective Case-Cohort Study. SHOCK Journal, March 2026PrePrintAbout Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the receipt of funding based on certain milestones, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America. View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-first-quarter-2026-financial-results-and-business-update-302772754.htmlSOURCE VolitionRx Limited Original: VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

$VNRX
New Article. VolitionRx is stacking catalysts heading into Q4 2026 — finger-prick sepsis detection, French reimbursement, a $5M vet milestone, and licensing talks with 10 major diagnostics players. Revenue up 40%. Not financial advice. DYOR.
https://allcapresearch.com/f/volitionrx-vnrx-stacking-catalysts-into-q4-2026

$EXAS
$ILMN

$PACB

$NTRA

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business UpdateMay 11, 2026 8:19 AM
PR Newswire (US) Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., May 11, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Friday, May 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2026 and to provide a business update. Details of this event can be found below.Event: VolitionRx Limited First Quarter 2026 Earnings and Business Update Conference Call Date:  Friday, May 15, 2026Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll free)Toll/International: 1-201-493-6779Conference ID:   13760656Louise Batchelor, Group Chief Marketing & Communications Officer of Volition will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the first quarter 2026, subsequent events and upcoming milestones.A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until May 29, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13760656.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.Media Enquiries:Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620 View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-first-quarter-2026-earnings-conference-call-and-business-update-302768143.htmlSOURCE VolitionRx Limited Original: VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

$VNRX- VolitionRx just hit a breakthrough — finger-prick nucleosome detection now possible. Add a Mayo Clinic validation study, 40% revenue growth in 2025, and France reimbursement expected Q4 2026, and this early-stage biotech is one to watch. Real science. Real potential. 🧬 #Biotech #VNRX

Strong news.

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in CatsMay 6, 2026 8:17 AM
PR Newswire (US) The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone paymentHENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in the species2. At 97% specificity the assay detected 86% of feline lymphomas1. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. Dr Annalisa Canale, Volition and first author on the paper commented:"Feline oncology lacks tumor biomarkers and so cancer in cats have been notoriously difficult to diagnose early."Building on our prior findings for canine lymphoma3-5, this study aimed to highlight the utility of circulating nucleosomes as biomarker to differentiate healthy vs intermediate-large cell lymphoma in cats."Nucleosome levels were significantly higher in cats with intermediate-large cell lymphoma compared to healthy controls indicating the potential role of H3.1-nucleosomes as a new useful biomarker for screening intermediate-large cell lymphoma in cats."Gael Forterre, Chief Commercial Officer, Volition commented:"This represents a tremendous commercial opportunity for Volition:the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment; andwe  plan to generate ongoing revenue in this large and growing market where our technology meets an unmet need."Our mission is to make cancer screening a routine part of every pet's annual wellness check and following the successful international rollout of our canine cancer test, we have now demonstrated that our technology is also effective for cats."We look forward to completing product development and making the Nu.Q® Vet Feline Test available through our distribution networks including reference laboratories and point-of-care platforms."The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space."The Nu.Q® Vet Feline Test taps into a significant, rapidly growing market:Large Population: There are approximately 73.8 million pet cats in the United States alone6.High Risk: It is estimated that approximately 1 in 5 cats will develop cancer in their lifetime7. Feline lymphoma, the most common cancer in the species, is a primary target for the Nu.Q® assay.The "Senior" Segment: Over 25% of U.S. cats are considered seniors (aged 8+)8, representing a recurring annual screening opportunity for over 18 million pets in the U.S.6,8Market Growth: The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster Compound Annual Growth Rate than the canine segment due to increasing owner awareness and a growing focus on feline-specific treatments"9.The paper should be available on a preprint service in the coming days.Data on FileVail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.H. M. Wilson-Robles et al, BMC Vet Res, 2022, https://doi.org/10.1186/s12917-022-03429-8C. Dolan et al, BMC Vet Res, 2021 https://doi.org/10.1186/s12917-021-02991-xH. M. Wilson-Robles et al, BMC Vet Res, 2021, https://doi.org/10.1186/s12917-021-02934-6AVMA Pet Ownership Sourcebook (2025) & APPA National Pet Owners Survey (2025)Can Cats Get Cancer? Understanding Feline Cancers Like Lymphoma & SCC. ImprimedData on file, Volition TAM modelTowards Healthcare: Veterinary Oncology Market Insights (October 2025)About Volition About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities, milestone payments and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.rNuQ™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.Image - https://mma.prnewswire.com/media/2973726/VolitionRx_Limited.jpg View original content to download multimedia:https://www.prnewswire.com/news-releases/volitionrx-announces-submission-of-manuscript-for-nuq-vet-cancer-test-in-cats-302764020.htmlSOURCE VolitionRx Limited Original: VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

I keep expecting to hear from the lung cancer trial in Taiwan. The RS is a price killer. Hard to be upbeat. Thanks for the link to the chart though.

VNRX.........................................https://stockcharts.com/sc3/ui/?s=VNRX&p=w&b=5&g=0&id=p86431144783

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis TestingApril 29, 2026 8:17 AM
PR Newswire (US)

HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype. This finger prick sample test could be used at the bedside, in the ER, or even at home in a self-test lateral flow kit, similar to COVID-19 or pregnancy testing, thereby greatly expanding the potential market beyond centralized lab testing.







Volition has previously announced results demonstrating correlation between whole venous blood (standard blood draw from the arm) samples utilizing its lateral flow prototype, and those of Volition's established automated Nu.Q® nucleosome assay performed in a central laboratory.This study, part of the SUMMIT program, tested capillary blood samples from hospital patients in Intensive Care using a lateral flow finger-prick prototype and demonstrated the detection of nucleosomes in those samples. Results showed the feasibility of early detection of immune disruptions that can occur in a range of conditions including sepsis, simply and rapidly when using the test in a variety of settings (doctor's office, Emergency Department, Intensive Care Unit setting, or home self-test), without the need to send a blood sample to a hospital laboratory for testing.Dr. Gaetan Michel, Chief Operating Officer, Volition said:"This prototype technology has the exciting potential to strengthen our product portfolio by addressing critical unmet diagnostic needs with an accessible, cost-effective solution enabling rapid, minimally invasive, Point-Of-Care self- testing."By enabling decentralized testing, our total addressable market expands, and we plan to target NGO partnerships and strategic collaborations with companies active in low income countries to accelerate commercialization and market penetration."We are excited to announce this breakthrough and look forward to sharing full details of the study and commercial updates throughout the year."Mr. Cameron Reynolds, Chief Executive Officer, Volition said:"The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a finger-prick sample and simple lateral flow device could enable quicker clinical decision making and consequently better patient outcomes.  "We believe that this is a first-in-class breakthrough which positions Volition as a pioneer in capillary blood-based nucleosome diagnostics, unlocking a new and highly scalable, portable testing modality. To our knowledge, this is the first reported finger-prick lateral flow test to quantify nucleosomes, a marker of NETosis and diseases such as sepsis. Our aim going forward is to provide not just a positive-negative test, but also to give a quantitative readout to facilitate clinical decision-making on a low-cost platform suitable for widespread adoption around the world."With recent estimates indicating approximately 166 million cases of sepsis worldwide the addressable market is huge. All-cause sepsis related deaths in 2021 represented 31.5%1 of total global deaths, with the highest burden of mortality in lower-middle-income countries.""This is a potential gamechanger, not only in diseases where time is critical such as sepsis, but also in significantly expanding potential use cases beyond traditional hospital infrastructure.  It also creates a compelling pathway into underserved low-income countries, where laboratory infrastructure may be weak or non-existent."Gray, Authia P et al.  Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. doi: 10.1016/s2214-109x(25)00356-0About SUMMIT (Sepsis: addressing unmet needs for disease monitoring with a rapid test)This innovative project, aimed at developing a capillary blood-based lateral flow test for the early diagnosis of sepsis, is carried out with the financial support of the Walloon Region.About Lateral Flow TestsThe first commercial Lateral Flow Test (LFT), the Clearblue pregnancy test, was launched in the late 1980s. More recently, LFTs for COVID-19 virus were widely used during the COVID-19 pandemic. LFTs are designed rapidly to detect a molecule of interest in a simple test that can be conducted immediately on a patient's blood, urine or saliva sample in a doctor's office or even a home setting by a person with no scientific training and using no specialized equipment.About Volition's Nu.Q® Nucleosome Assay The Volition Nu.Q® nucleosome assay is a chemiluminescent immunoassay (ChLIA) that currently runs on the  Immunodiagnostic Systems (IDS) i10® automated analyzer platform. It holds a CE Mark to aid in the detection and evaluation of diseases associated with NETosis and is available in 27 European Countries.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.rNuQ™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.Photo - https://mma.prnewswire.com/media/2968036/VolitionRx_Limited_Photo.jpg



View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-announces-breakthrough-finger-prick-detection-of-nucleosomes-expanding-global-market-potential-for-sepsis-testing-302755982.htmlSOURCE VolitionRx Limited

Original: Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

VolitionRx Announces Acceptance of Compliance Plan by NYSE AmericanApril 23, 2026 8:12 AM
PR Newswire (US)

HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, the NYSE American LLC (the "NYSE American") accepted the Company's plan of compliance for continued listing on the exchange.As previously reported, on February 6, 2026, the Company received a notice from the NYSE American stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years, and Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.  The notice also indicated that the Company was not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million among other things).The Company was required to submit a plan to the NYSE American by March 8, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. The Company submitted a plan prior to the deadline.On April 22, 2026, the Company received a notification (the "Acceptance Letter") from the NYSE American that the Company's previously submitted plan to regain compliance with the NYSE American's listing standards (the "Plan") was accepted. In the Acceptance Letter, the NYSE American granted the Company until August 6, 2027 (the "Plan Period") to regain compliance with the continued listing standards.During the Plan Period, the Company will be subject to periodic review by the NYSE American on its progress with the goals and initiatives outlined in the Plan. The Company intends to take all reasonable measures available to regain compliance with Sections 1003(a)(i), (ii) and (iii) of the Company Guide during the Plan Period. If the Company does not regain compliance with the NYSE American listing standards by August 6, 2027, or if the Company does not make sufficient progress consistent with the Plan during the Plan Period, then NYSE American may initiate delisting proceedings.The Acceptance Letter has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during the Plan Period, subject to the Company's compliance with the other listing requirements of the NYSE American. The Acceptance Letter does not affect the Company's ongoing business operations or its reporting requirements with the Securities and Exchange Commission.About VolitionVolition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.Media Enquiries
Louise Batchelor, Volition mediarelations@volition.com
+44 (0)7557 774620Cautionary Note Regarding Forward-Looking StatementsStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the Company's expectations surrounding regaining compliance with the NYSE American's continued listing standards, and actions of the Company and/or the NYSE American to be taken with respect to matters discussed in the notice and the Acceptance Letter. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to the Company's ability to regain compliance with the listing standards set forth in the Company Guide by August 6, 2027, as well as the risks disclosed in other documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.



View original content:https://www.prnewswire.com/news-releases/volitionrx-announces-acceptance-of-compliance-plan-by-nyse-american-302751633.htmlSOURCE VolitionRx Limited

Original: VolitionRx Announces Acceptance of Compliance Plan by NYSE American

Volition Launches rNuQ™ Webshop Broadening Product RangeApril 20, 2026 7:30 AM
PR Newswire (US)

HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we have developed over the past 10 years.We have developed a range of cutting edge controls for our own products, and they should be very useful in a range of research settings. Given our shift to commercialization, we are now opening up these for sale through an online offering.Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented:"We are delighted to launch our extensive  range of off-the-shelf recombinant nucleosomes through this easy-to-use website. Manufactured in an ISO 13485 certified facility, delivering exceptional reproducibility and quality control, Volition's nucleosomes are stored and shipped at +4 °C in a glycerol-free buffer, simplifying handling while preserving structural integrity and experimental performance."This is a further expansion of our Nu.Q® Discover pillar, where we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug development across multiple therapeutic areas. Some of these pharmaceutical companies have progressed to late stage clinical trials using our assays as pharmacodynamic biomarkers."We are excited now to expand our offering with this broad range of ready to use recombinant nucleosomes for research use, and potentially in the future as part of other products."We are also in discussion with several pharmaceutical companies for the bespoke development of assays, expanding from blood plasma to other types of biospecimens. "We believe our rNuQ™ webshop, where one can browse, click and buy, will provide rapid access to high-quality nucleosomes for epi-drug researchers worldwide and potentially a new source of revenue on our path to commercializing our very large IP portfolio."In 2025 we delivered 86% revenue growth for Nu.Q® Discover and anticipate a similar trajectory in 2026." About the rNuQ ShopWith off-the-shelf recombinant nucleosome configurations, this portfolio provides a wide range of  commercial nucleosomes  for research use.Researchers can select nucleosomes based on histone composition, post-translational modifications (PTMs), and citrullination patterns, with options to tailor key parameters to specific experimental needs.Unlike many chromatin reagents, Volition nucleosomes are stored and shipped at +4 °C in a glycerol-free buffer, simplifying handling while preserving structural integrity and experimental performance.The range includes precisely defined PTMs, engineered citrullination patterns, and exclusive H3K18lactylations nucleosomes, some of which are not currently available from any other suppliers.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.rNuQ™, Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volition-launches-rnuq-webshop-broadening-product-range-302747084.htmlSOURCE VolitionRx Limited

Original: Volition Launches rNuQ™ Webshop Broadening Product Range

VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business UpdateMarch 31, 2026 4:05 PM
PR Newswire (US)

Conference call to discuss financial and operational results scheduled for
Wednesday, April 1 at 8:30 a.m. U.S. Eastern TimeHENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the full fiscal year 2025.  Volition management will host a conference call tomorrow, April 1 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.Cameron Reynolds, President and Group Chief Executive Officer, said:"We set out over fifteen years ago to help save lives and improve outcomes for millions of patients worldwide, and I could not be prouder of the progress we are making towards that goal."In 2025 we not only received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced the inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed  program (~$7.3 million) in France."Cancer and sepsis are leading causes of death, accounting for approximately one third of deaths worldwide. Our tests are about to be used in both these devastating diseases, to help save lives in real world hospital settings: an extremely proud moment for our entire team."Our goal is to secure a range of licensing agreements in the human diagnostics space and to that end we are in discussions with around 10 of the world's leading diagnostic and liquid biopsy companies and are at various stages of the process across our different pillars, ranging from due diligence to tech transfer, to evaluation of clinical samples, to contract negotiation. We anticipate further human licensing deals and will update on progress as they are completed."I believe we will look back on 2025, this first quarter of 2026 and indeed in time, the next few quarters, as transformational for the company."Financial HighlightsFinished the year strongly with year over year revenue growth for Q4 of 133%.Full-year revenue for 2025 was $1.7 million, representing growth of 40% over the previous year.Operating expenses for the year were down $4.8 million, or 17% compared to last year.Net loss was down 14% for the year versus 2024.Net cash used in operating activities was $19.7 million for the year, down 24%.Subsequent to year end, we received:$5.4 million in net proceeds from equity sales through our at-the-market facility,$1.9 million in net proceeds from issuance of a convertible note and warrant, and$1 million of non-dilutive funding from agencies of the Walloon Region, with an additional approximate $0.9 million expected to be received in tranches based on certain time and event milestones over the next 12 months.Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference Call
Date:  Wednesday, April 1, 2026
Time:  8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID:  13759627Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr. Andrew Retter, Medical Consultant and Dr. Jake Micallef, Chief Scientific Officer. The call will provide an update on important events that have taken place in 2025, subsequent events and upcoming milestones.A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until April 15, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13759627.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the receipt of funding based on certain milestones, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Pursuant to the disclosure requirements of the NYSE American Company Guide Section 610(b), Volition is reporting that its audited consolidated financial statements for the fiscal year ended December 31, 2025, included in Volition's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to Volition's ability to continue as a going concern. This announcement does not represent any change or amendment to Volition's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-full-fiscal-year-2025-financial-results-and-business-update-302730347.htmlSOURCE VolitionRx Limited

Original: VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in BelgiumMarch 31, 2026 8:16 AM
PR Newswire (US)

HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 million) in financing from Namur Invest ("NI") and Wallonie Entreprendre S.A. ("WE") in Belgium.Volition will use the proceeds from the financing for ongoing development of its Nu.Q® product portfolio, including taking forward its regulatory transition program for Nu.Q® NETs (from IVDD to IVDR), the continued research and development of a Lateral Flow product, specifically to enable access to its Nu.Q® NETs product in Low Income Countries and more.Mr. Nicolas Delahaye, Corporate Relations Manager, Namur Invest commented: 
"We are delighted to continue our support of the innovative work conducted by the team at Belgian Volition. 
"We hope that this funding can help Volition to expand their manufacturing capabilities and anchor their Research and Development efforts here in Wallonia"Mr. Géry Lefebvre, Investment Manager, WE added: 
"Supporting companies like Volition is core to our mission at Wallonie Entreprendre S.A.. Volition have developed a versatile technology platform and a strong Intellectual Property portfolio over the last fifteen years. 
"Through this financing, we aim to support key value inflection points, including clinical validation and the expansion of commercialization efforts, while reinforcing the anchoring of these strategic activities in Wallonia."Dr. Gaetan Michel, Chief Operating Officer of Volition, said: 
"We are enormously grateful to NI and WE for this latest financing, and for the ongoing financial assistance we have received from agencies within Wallonia. 
"This is a key part of our financing strategy to actively seek non-dilutive funding, as this provides additional cash at favorable terms to support the Company's continued development and anchorage in Wallonia. This latest funding takes the total non-dilutive funding from all sources to-date to over $25 million. 
"We are delighted with the great progress we are making on so many fronts and look forward to achieving many milestones throughout this year."About the Financing
Approximately $0.4 million of this non-dilutive funding was received in December 2025, approximately $1 million received in the first quarter 2026, with the additional approximate $0.9million to be received in tranches based on certain time and event milestones over the next 12 months.About Volition 
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. 
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. 
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volitionrx-secures-eur-2-0-million-of-non-dilutive-funding-from-regional-government-agencies-in-belgium-302729842.htmlSOURCE VolitionRx Limited

Original: VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma PatientsMarch 30, 2026 8:13 AM
PR Newswire (US)

Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock JournalHENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event and are even higher in those patients that go on to have complications from the trauma.Principal Investigator and Senior Author, Myung S. Park, Professor of Surgery, Associate Medical Director of Research, Trauma Center, Director, Clinical Research Trials Unit, Center for Clinical and Translational Science, Department of Surgery, Division of Trauma, Critical Care & General Surgery, Mayo Clinic, Rochester commented:"The identification of reliable biomarkers in trauma patients is a clinical challenge and remains an unmet need in the emergency and surgical setting."In this study we analyzed 674 trauma patients and found that levels of the H3.1 and H3R8 Citrulline nucleosomes are elevated early after traumatic injury, especially in those who developed Venous Thromboembolism ("VTE")."These findings underscore the importance of understanding the pathophysiology of nucleosomes in inducing VTE and their role as biomarkers.  These biomarkers could aid in early risk identification and may inform targeted preventive strategies in trauma care."We have continued to work with the Volition team and look forward to publishing further findings."Dr Andrew Retter, Medical Consultant, Volition commented:"This is significant, not only for clinicians, patients and their families, but also for Volition: a peer reviewed publication with the Mayo Clinic research team strongly supports our efforts to commercialize our Nu.Q® NETs product."This study, together with previously published evidence1-4 , demonstrates that Nu.Q® NETs may enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across acute and chronic conditions."The published paper can be found in link below:Circulating Nucleosomes are Elevated in Trauma Patients with Venous Thromboembolism: A Prospective Case-Cohort StudyMorimont et al. Biomolecules, 2022. https://doi.org/10.3390/biom12081038Rahimi et al, Ann Intensive Care 2023. https://doi.org/10.1186/s13613-023-01204-yDaan F.L. Filippini et al.. Critical Care, 2025. https://doi.org/10.1186/s13054-025-05415-6Neumann et al, MedRXIVAbout Mayo Clinic 
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volition-announces-mayo-clinic-study-demonstrates-nuq-concentrations-are-elevated-in-trauma-patients-302728558.htmlSOURCE VOLITION DIAGNOSTICS UK LIMITED

Original: Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer ConferenceMarch 26, 2026 8:17 AM
PR Newswire (US)

HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark this week. The poster highlighted the use of its Nu.Q® Cancer assays in the management of lung cancer patients.Poster 244P : Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation1Joint lead author Dr. Pei-Hsing Chen, Assistant Professor, Surgical Department, National Taiwan University Hospital, Taipei City, Taiwan, said:"A key finding from this study was that measuring preoperative H3K27Me3-nucleosomes using Volition's simple blood test allows us to identify which Non Small Cell Lung Cancer patients are most likely to benefit from closer follow-ups or secondary cancer treatment."While high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes, low H3K27me3 levels indicated significantly better outcomes."Volition's Nu.Q® H3K27Me3-nucleosome levels may also help identify micro-metastatic disease and support systemic treatment decision-making in high-risk patients."The Nu.Q® Cancer technology supports a practical approach to empower clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey."Dr Andrew Retter, Medical Consultant, Volition, said:"Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring."Research conducted by our long-term collaborators in Taiwan and Lyon1-4 consistently demonstrates that our Nu.Q® Cancer technology empowers clinicians to make more informed treatment decisions and provides valuable new monitoring capabilities throughout the patient journey."By enriching clinical prognostication, Nu.Q® Cancer helps identify the most appropriate treatment pathway for an individual patient, supporting efforts to improve overall survival and deliver patient-centred care."We are now on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives"Pei-Hsing Chen et al "Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation" Poster 244P ELCC 2026Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom13081255Couraud S, et al  Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG study. ELCC 2024 PosterMarie Piecyk et al, "H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer: interim results from the analysis of up to 832 patients at baseline" Poster 395 ELCC 2025About Volition About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volition-announces-abstract-demonstrating-risk-stratification-in-lung-cancer-presented-at-the-european-lung-cancer-conference-302726071.htmlSOURCE VolitionRx Limited

Original: Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business UpdateMarch 25, 2026 4:12 PM
PR Newswire (US)

Conference call to take place on Wednesday, April 1 at 8:30 a.m. U.S Eastern TimeHENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Wednesday, April 1 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the full fiscal year 2025 and to provide a business update. Details of this event can be found below.Event: VolitionRx Limited Full Fiscal Year 2025 Earnings and Business Update Conference Call
Date:  Wednesday, April 1, 2026
Time:  8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European TimeU.S. & Canada Dial-in: 1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID:  13759627Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr. Andrew Retter, Medical Consultant and Dr. Jake Micallef, Chief Scientific Officer. The call will provide an update on important events that have taken place in 2025, subsequent events and upcoming milestones.A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until April 15, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13759627.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620



View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-full-fiscal-year-2025-earnings-conference-call-and-business-update-302725247.htmlSOURCE VolitionRx Limited

Original: VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

VNRX......................https://stockcharts.com/sc3/ui/?s=VNRX&p=w&b=5&g=0&id=p86431144783

Volition Announces Detection of Over 95% of Early-Stage CancersMarch 25, 2026 8:17 AM
PR Newswire (US)

Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificityCapture-Seq™ Targets $36 Billion TAM in Early Cancer Detection and MRD.HENDERSON, Nev., March 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces compelling proof of concept data from a blinded validation cohort for the detection of cancer, including early stage cancer using its breakthrough Capture-Seq™ technology.

 

Dr. Jake Micallef, Chief Scientific Officer, Volition, commented:"As we reported previously, Volition has developed a new liquid biopsy method, Capture-Seq™, which enriches and purifies plasma samples resulting in virtually pure circulating tumor DNA (ctDNA) samples for analysis."We are now releasing the data from a blinded validation cohort of 81 subjects (colorectal and lung cancer patients = 59, healthy controls = 22) and are extremely encouraged by the results, particularly in early-stage cancer detection.Details are summarized in the table below1:Cancer StageDetection RateI94% (17/18)II96% (26/27)III100% (2/2)IV91% (10/11)Unknown0% (0/1)All StagesSensitivity= 93% (55/59)ControlsSpecificity= 95% (21/22)"Volition is, I believe, the first liquid biopsy company to focus on circulating cell free nucleoproteins and we have filed a number of new patents to protect this technology."Dr. Andrew Retter, Medical Consultant, Volition, commented:"From a clinical perspective, the proof of concept and early blinded validation results are extremely encouraging, and the early-stage cancer detection of 95% of stage I and II cancers is particularly noteworthy."For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to Multi-Cancer Early Detection (MCED) fulfilling a significant unmet clinical need."We also believe Capture-Seq™ has the potential to play a role in cancer management, including but not limited to, Minimal Residual Disease detection and treatment monitoring, either alone or potentially in combination with other technologies too."Mr. Gael Forterre, Chief Commercial Officer, Volition, added:"This scientific breakthrough has generated a lot of interest with potential licensing partners, and we are excited to share this early-stage detection data."We feel that this technology could, with further development, become very widely used, in both the human and veterinary markets, and fits very well with our Nu.Q® product portfolio. "We believe this represents a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $23 billion2 for the human MCED use, and over $13 Billion2 for MRD."We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible."About Capture-Seq™The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.In a recently submitted manuscript we report a new, two-step method for preparing pure circulating tumor DNA data sets for cancer patients:physical enrichment of the sample andbioinformatic removal of virtually all remaining non-tumor cfDNA sequences from the DNA sequence data set.This new method produced >99% pure ctDNA sequencing data sets for blood samples from cancer patients and, whilst we capture a subset of the ctDNA (i.e. not all the ctDNA in a sample), it is virtually pure cancer DNA. These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers.###Data on FileData on File: Volition TAM ModelAbout Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com,+44 (0)7557 774620
Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.Video: https://www.youtube.com/watch?v=I7QlzSELJs0 



View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-announces-detection-of-over-95-of-early-stage-cancers-302724580.htmlSOURCE VolitionRx Limited

Original: Volition Announces Detection of Over 95% of Early-Stage Cancers

Another mover

VNRX...............................................p/m

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNAMarch 18, 2026 8:17 AM
PR Newswire (US)

Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.HENDERSON, Nev., March 18, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is the first to demonstrate the isolation and analysis of >99% pure circulating tumor-derived DNA (ctDNA). Volition announces the submission of an updated manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy1". The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells. In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.Dr Jake Micallef, Chief Scientific Officer, Volition commented:"Distinguishing cancer derived plasma DNA from healthy DNA when the two are mixed is problematic. When the cancer DNA makes up 1% or less of the total DNA it is extremely problematic.  Moreover, DNA from cancer and healthy cells has the same double helix structure and has never before been separated chemically."Our manuscript, submitted in November and previously announced in December 2025, described a new liquid biopsy chemistry for isolating CTCF-DNA from plasma. Our continuing work on CTCF-bound DNA has revealed what we believe to be an unprecedented new discovery; that there is almost no CTCF-bound DNA in healthy plasma and almost all CTCF-bound DNA in the blood of a cancer patient is derived from cancer cells – i.e. it is virtually pure circulating tumor-derived DNA."Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years."In this updated manuscript we report a new, two-step method for preparing pure circulating tumor DNA data sets for cancer patients:i.  physical enrichment of the sample and
ii. bioinformatic removal of virtually all remaining non-tumor cfDNA sequences from the DNA sequence data set."This new method produced >99% pure ctDNA sequencing data sets for blood samples from cancer patients and, whilst we capture a subset of the ctDNA (i.e. not all the ctDNA in a sample), it is virtually pure cancer DNA. "These methodological and technological breakthroughs represent a novel liquid biopsy method for a novel class of potentially thousands of liquid biopsy sequence biomarkers.We call this technology "Capture-Seq™" and it shows potential for both a multi-cancer early detection (MCED) approach, either alone or in combination with other tests, and the detection of Minimal Residual Disease."Volition is, I believe, the first liquid biopsy company to focus on circulating cell free nucleoproteins and we have filed a number of new patents to protect this technology."Dr Andrew Retter, Medical Consultant, Volition commented:"From a clinical perspective, the proof of concept and early blinded validation results reported in this paper are extremely encouraging. In two independent cohorts we reported no false positives and detected 49/49 cancers in the first cohort (including 23 early stage I/II and 21 controls) and validated it in a second blinded cohort with 13/14 later stage cancers detected with 10 additional controls  We are now working on a further validation cohort of early stage cancers, and expect this data soon."For patients, the potential significance is huge. If validated in larger cohorts, CTCF Capture-Seq™ could contribute to multi-cancer early detection and disease management, particularly in combination with Volition's existing Nu.Q® assay for lung cancer (H3K27me3) but potentially in combination with other technologies too."Mr. Gael Forterre, Chief Commercial Officer, Volition added:"This scientific breakthrough has generated a lot of interest with potential licensing partners."We feel that this technology could, with further development, become very widely used, in both the human and potentially the veterinary market, not only for multi-cancer early detection but also the detection of Minimal Residual Disease. "We believe this represents a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $23 billion2 for the human MCED use, and over $13 Billion2 for MRD."We are in active discussions with several large liquid biopsy and diagnostic companies to accelerate the development and launch of this technology as soon as possible."The updated paper should be available on the preprint service Research Square in the coming days.LINK TO Research SquareData on File : Volition TAM ModelAbout Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.Video - https://www.youtube.com/watch?v=R11jftp4Vcw 





View original content to download multimedia:https://www.prnewswire.com/news-releases/volition-reports-breakthrough-in-liquid-biopsy-achievement-of-over-99-purity-in-isolating-cancer-dna-302717364.htmlSOURCE VolitionRx Limited

Original: Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet SystemsMarch 6, 2026 8:10 AM
PR Newswire (US)

HENDERSON, Nev., March 6, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the completion of all validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, allowing use of full automation rather than manual plates in central laboratories.Junichi Makino, President and Representative Director at Fujifilm Vet Systems, said: "We are excited to be the first in the world to utilize this centralized lab automation for the Nu.Q® Vet Cancer Test, this is a big step forward from the current use of manual plates."Since our launch of the Nu.Q® Vet Cancer Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians, indeed the number of veterinary hospitals registered to use the test in Japan already exceeds 1,700."This automated test will enable a more rapid turnaround and high throughput to meet increasing demand."Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition added:"There are approximately seven million pet dogs in Japan. Given Fujifilm Vet System is a leading provider of diagnostic tests  in this large market, it presents an exciting revenue opportunity for Volition."Cancer is the leading cause of adult canine deaths and earlier detection can improve outcomes. The Nu.Q® Vet Cancer Test is an accessible and affordable screening tool for dogs to aid in early cancer detection."This automated test via the Immunodiagnostic Systems (IDS) i10® automated analyzer platform is the same platform Volition utilizes for its human products: Nu.Q® Cancer, Nu.Q® NETs and Nu.Q® Discover, demonstrating the synergy across not only the Nu.Q® technology platform but also between humans and dogs."Volition's supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test throughout its network of central reference laboratories in Japan.  About FujiFilm Vet SystemsFujiFilm Vet Systems is a subsidiary of FujiFilm Holdings Corporation, listed on the Tokyo stock exchange under ticker 4901.FujiFilm Vet Systems provides testing services centered on health checkups to veterinary medical facilities nationwide with relationships throughout the estimated 11,000 veterinary medical facilities in Japan. FujiFilm Vet Systems can also handle specialized examinations that cannot be performed at veterinary hospitals. In addition, they have established central reference laboratories at 10 bases in Japan and have led the market by providing services that quickly report test results by utilizing  their testing and specimen collection network.About Volition Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.Media Enquiries:Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volition-announces-first-ever-automated-nuq-vet-cancer-test-with-fujifilm-vet-systems-302706601.htmlSOURCE VolitionRx Limited

Original: Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

VNRX...........................https://stockcharts.com/sc3/ui/?s=VNRX&p=w&b=5&g=0&id=p86431144783

VolitionRx Highlights Commercial Momentum and Multi-Pillar ExecutionFebruary 25, 2026 8:10 AM
PR Newswire (US)

HENDERSON, Nev., Feb. 25, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is pleased to provide a consolidated update on the significant clinical and commercial progress achieved over recent months.Key Highlights:Capture-Seq™ Platform: Paper recently submitted for peer review, underscores a $23 billion[1] annualized opportunity in cancer detection.Lung Cancer: Reimbursement submission in France on track; routine clinical use expected by Q4 2026.Veterinary Breakthrough: 100% specificity achieved in Feline Lymphoma study; $5M milestone payment anticipated.Sepsis & NETosis Validation: Inclusion of the Nu.Q® NETs assay in the $7.3 million government-backed DETECSEPS program in France.Licensing Momentum: Company confirms active discussions with ~10 global diagnostic leaders.Capture-Seq™ Breakthrough in Cancer Detection.We were delighted to submit for peer review a manuscript entitled "Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy." This paper showcases both a new method, Capture-Seq™, and new biomarkers for the detection of cancer, holding the promise of accurate, low-cost tests for a wide range of cancers.This scientific breakthrough has generated a lot of interest with potential licensing partners. We feel that this technology could, with further development, become very widely used and are actively seeking large commercial partner/s to work with us to accelerate the integration and launch of this technology as soon as possible.We believe this represents a significant commercial opportunity with a Total Addressable Market on an annualized basis of approximately $23 billion[1].Lung Cancer Reimbursement SubmissionIn the fourth quarter of 2025, we received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer and in January were delighted to announce that preparation of the reimbursement submission is underway, actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system. Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the fourth quarter, 2026.Government Funded Interventional Sepsis StudyIn December, we also announced the inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed (~$7.3 million) program in France. The DETECSEPS program provides an opportunity to receive individualized or personalized care, adjusted to the risk of deterioration and progression to sepsis.Consequently, our tests are expected to be used this year in cancer and sepsis, both devastating diseases, to help save lives in real world hospital settings: an extremely proud moment for our entire team.Cancer and sepsis are leading causes of death, accounting for approximately a third of deaths worldwide[2-4]. With the first clinical use now imminent, we are about to be part of the solution, through simple, easy to use, low-cost tests.New Clinical Utility in Hidradenitis SuppurativaIn January, we announced data demonstrating the use of our Nu.Q® NETs assay in patient management for Hidradenitis Suppurativa (HS), a lifelong disease which affects approximately 1% of the world's population[5].Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD. co-author of the paper said:"The findings described in the manuscript demonstrate that for the first time an easy-to-measure blood test, Nu.Q® NETs, can be used to classify patients and to surrogate response to treatment. "In addition, given the various biologic therapies being investigated, circulating H3.1-nucleosomes is a new blood marker in HS that may be used to initiate trials where treatment guidance for both initiation and early cessation of treatment will be studied."The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries not in the EU (Iceland, Liechtenstein, and Norway) and the U.K.Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis. The market opportunity for such indications is significant, with a Total Addressable Market of $3.8 billion[1].Breakthrough Cat ResultsWe have also reported breakthrough results from a clinical study demonstrating the high accuracy of our Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species[6]. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas[7]. This breakthrough marks the development of what we expect to be the world's first simple, affordable blood-based liquid biopsy test for feline cancer, a significant unmet need in veterinary medicine. This represents a tremendous commercial opportunity for Volition:the publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment.we will also generate ongoing revenue, in this large and growing market where our technology meets an unmet need.The Nu.Q® Vet Canine test is already available in more than 20 countries, and we believe the addition of a feline equivalent could potentially double our total addressable market in the companion animal space[1].Our Goal and VisionOur goal is to secure a wide range of licensing agreements in the human diagnostics space, mirroring our successful strategy in the veterinary market, and we anticipate diverse deal structures, with potential for up-front and milestone payments, and future recurring revenue.We have developed a truly remarkable, versatile platform and have further strengthened our Intellectual Property portfolio as we continue our licensing discussions with around 10 of the world's leading diagnostic and liquid biopsy companies. These discussions are at various stages of the negotiation process across all our different pillars, and we anticipate announcing additional agreements during 2026.Our vision is for our technologies to be incorporated into tests that will be used first by millions, and ultimately, hundreds of millions of people and animals a year, with our platform licensed to a range of large diagnostic and liquid biopsy companies (and governments) worldwide. Combining our groundbreaking technology with their installed base of laboratories, analyzer machines and sales forces around the world will achieve the optimal outcome for us – large companies have the resources to realise the opportunities better than Volition.The Total Addressable Markets[1] (TAMs) for our technologies, on an annualised basis, are multi-billion-dollar opportunities, not only for Volition, but for our licensing partners. Volition has made strong progress, both clinically and commercially, and our technology is now poised to be used very widely in a broad range of clinical utilities.Summary of Addressable Markets (TAM)[1]PillarEstimated Annualized TAMStatusCapture-Seq™ Cancer Detection$23 BillionManuscript in Peer ReviewNu.Q® NETs (Sepsis/Chronic)$3.8 BillionCE-Marked / Clinically AvailableNu.Q® Vet (Canine/Feline)$1.0+ BillionCanine is Commercially Available Data on File: Volition TAM Model.Gray, Authia P et al. Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. doi: 10.1016/s2214-109x(25)00356-0.Haem Rahimi M, et al. Association of pronounced elevation of NET formation and nucleosome biomarkers with mortality in patients with septic shock. Ann Intensive Care. 2023 Oct 17;13(1):102. doi: 10.1186/s13613-023-01204-y.Morimont, L., et al. (2022). NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study. Biomolecules, 12(8), 1038. doi: 10.3390/biom12081038Bouazzi D, Nielsen SM, Hagan PG, et al. JAMA Dermatol. 2025. https://doi.org/10.1001/jamadermatol.2025.2373.Vail D, Thamm D, Liptak J, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier Health Sciences; 2019.Data on File, Volition.About Volition About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: 
Louise Batchelor
Volition
mediarelations@volition.com
+44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution-302696927.htmlSOURCE VolitionRx Limited

Original: VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

Getting really UGLY. I'll know where to find losses to offset gains. This is what you get when you put money into pennies. Like the technology but the chart is not looking good and cannot seem to find bottom today.

VNRX...........................................https://stockcharts.com/sc3/ui/?s=VNRX&p=w&b=5&g=0&id=p86431144783

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsFebruary 9, 2026 5:20 PM
PR Newswire (US)

HENDERSON, Nev., Feb. 9, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on February 6, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years and Section 1003(a)(iii) of the Company Guide requiring a company to have stockholders' equity at least $6.0 million if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years.  The Notice also indicates that the Company is also not currently eligible for any exemption in Section 1003(a) of the Company Guide (including the exemption provided for companies with total value of market capitalization exceeding $50 million among other things).In connection with its non-compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii), the Company must submit a plan (the "Plan") to the NYSE American by March 8, 2026, advising of actions it has taken or will take to regain compliance with the continued listing standards by August 6, 2027. If the NYSE American determines to accept the Plan, the Company will be notified in writing and will be subject to periodic reviews, including quarterly monitoring for compliance with the Plan.  If the Company does not submit a plan or if the Plan is not accepted, NYSE American will commence delisting proceedings. Furthermore, if the Plan is accepted but the Company is not in compliance with the continued listing standards by August 6, 2027 or if the Company does not make progress consistent with the Plan, the NYSE American will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide.The Notice has no immediate impact on the listing of the Company's shares of common stock, which will continue to be listed and traded on the NYSE American during this period, subject to the Company's compliance with the other listing requirements of the NYSE American. The common stock will continue to trade under the symbol "VNRX", but will have an added designation of ".BC" to indicate the status of the common stock are "below compliance". The Notice does not affect the Company's ongoing business operations or its reporting requirements with the U.S. Securities and Exchange Commission.The Company is committed to achieving compliance with the NYSE American's requirements and intends to submit a plan to the NYSE American on or before March 8, 2026 that will regain compliance with the NYSE American continued listing standards by August 6, 2027. However, there can be no assurance that the Company will be able to achieve compliance with the NYSE American's continued listing standards within the required timeframe.About VolitionVolition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life- altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.Media Enquiries
Louise Batchelor, Volition mediarelations@volition.com
+44 (0)7557 774620Cautionary Note Regarding Forward-Looking StatementsStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements reflect the current beliefs and expectations of management and include statements regarding the Company's expectations surrounding the submission of a plan and regaining compliance with the NYSE American's continued listing standards, and actions of the Company and/or the NYSE American to be taken with respect to matters discussed in the Notice. . All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Volition believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.Forward-looking statements are subject to risks and uncertainties that may cause Volition's actual activities or results to differ materially from those indicated or implied by any forward-looking statement, including, without limitation, due to risks and uncertainties related to the Company's ability to timely submit its plan to the NYSE American, the acceptance of its plan by the NYSE American and the Company's ability to regain compliance with the listing standards set forth in the Company Guide by August 6, 2027, as well as the risks disclosed in other documents Volition files from time to time with the SEC, including Volition's Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.



View original content:https://www.prnewswire.com/news-releases/volitionrx-receives-notice-of-non-compliance-with-nyse-american-continued-listing-standards-302683021.htmlSOURCE VolitionRx Limited

Original: VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa FoundationFebruary 4, 2026 8:45 AM
PR Newswire (US)

 Showing New Indication for Nu.Q® NETs HENDERSON, Nev., Feb. 4, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the sponsorship of a symposium at the European Hidradenitis Suppurativa Foundation (EHSF) Conference in Malta on 5th February. The session entitled "Empowering Precision-medicine approach through NETs Plasma Biomarker-driven personalized treatment"  will be presented by Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital, Athens, Greece.Professor Evangelos J. Giamarellos-Bourboulis commented:"The scientific program at the EHSF conference this year provides a focus on genetics and updates on basic research, including the diagnosis and management of Hidradenitis Suppurativa (HS)."I am delighted to present data from the recently released clinical study demonstrating the use of Volition's  Nu.Q® NETs assay in patient management for HS, a chronic lifelong disease, which affects approximately 1% of the world's population1."Since the advent of biologicals in the treatment of HS, there has been growing evidence that treatment response varies greatly so that some patients may experience substantial improvement, others no benefit at all and some may even worsen."Those considerations call for a precision medicine approach, which will be the focus of the Symposium. The findings from our study demonstrate that for the first time an easy-to-measure blood test, Nu.Q® NETs, can be used to classify HS patients and help guide treatment selection and modification."In addition, given the various biologic therapies currently in development, we will also explore the potential use of circulating H3.1 nucleosomes as a biomarker for ongoing and future clinical studies."Our hope is that trials can be started to study if Nu.Q® NETs can be used to guide both treatment initiation and early cessation of treatment."Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition added:"We are honored that leading expert Professor Giamarellos-Bourboulis is presenting the findings of his clinical study at the Volition sponsored symposium event at the EHSF Conference this week."This study, together with previously published evidence2-5 , demonstrates that Nu.Q® NETs should enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across both acute and chronic conditions."The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries (Iceland, Liechtenstein, and Norway) and the U.K."Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis. The market opportunity for such indications is significant, with a Total Addressable Market of $3.8 billion6."A poster entitled "Change of Neutrophil Extracellular Traps (NETs) Blood Levels to Surrogate Response to Treatment in Hidradenitis Suppurativa" will also be presented at the Conference on Wednesday, February 4.The recently released paper can be found in link below:Plasma H3.1-Nucleosomes to Classify Severity and Surrogate Response to Treatment in Hidradenitis Suppurativa : A Cohort Study
 Bouazzi D, Nielsen SM, Hagan PG, et al. JAMA Dermatol. 2025. https://doi.org/10.1001/jamadermatol.2025.2373 Morimont et al. Biomolecules, 2022.  https://doi.org/10.3390/biom12081038Rahimi et al, Ann Intensive Care 2023. https://doi.org/10.1186/s13613-023-01204-yDaan F.L. Filippini et al.. Critical Care, 2025. https://doi.org/10.1186/s13054-025-05415-6Neumann et al, MedRXIVData on File: Volition TAM Model.About Hidradenitis SuppurativaHidradenitis suppurativa (HS) is a lifelong, recurring condition that is often difficult to manage. The exact cause of HS is unknown however it is beyond any doubt a chronic neutrophilic disease.HS is a painful skin condition that causes skin abscesses and scarring on the skin. It is thought to affect about 1 in 100 people.It is important to recognise and diagnose the condition, including flare-ups, to prevent it getting worse. although the symptoms may improve or eventually stop with treatment.The condition can have a significant impact on a person's everyday life. Having to regularly change dressings and constantly live with the pain and discomfort of the symptoms can affect a patient's  quality of life and lead to depression.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620Safe Harbor StatementStatements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.



View original content:https://www.prnewswire.com/news-releases/volition-sponsors-symposium-at-15th-conference-of-the-european-hidradenitis-suppurativa-foundation-302678836.htmlSOURCE VolitionRx Limited

Original: Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

VNRX....................................https://stockcharts.com/sc3/ui/?s=VNRX&p=w&b=5&g=0&id=p86431144783

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer AssaysJanuary 30, 2026 8:50 AM
PR Newswire (US)

HENDERSON, Nev., Jan. 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the preparation of the reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by the Hospices Civils de Lyon (HCL), France's second largest university hospital system, and will run in parallel with the previously announced process to achieve clinical certification of the test at HCL.Professor Léa Payen, Professor in Toxicology and Biochemistry, Claude Bernard University of Lyon I and Hospices Civils de Lyon, France commented:
"We are keen to support the submission of Volition's reimbursement dossier for its Nu.Q® Cancer assays so that we can introduce the test into routine, reimbursed clinical practice in France, through our extensive hospital network, for lung cancer management as soon as possible, hopefully later this year.""We have worked closely with the Volition team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q® in the management of cancer patients. Our results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q® test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care." [1-3]"Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring. This is a test we plan to use routinely."Frederic Wuilque, Vice President, Global Products, added:"With the active support of HCL, we are working towards the submission of our reimbursement dossier before the end of this quarter under the framework of the "Innovative Procedures Outside the Nomenclature" (RIHN-référentiel des actes innovants hors nomenclature).  Once the dossier is classified as admissible, we understand that determination of eligibility for reimbursement coverage is mandated to take no more than five months.""There are approximately 50,000 new lung cancer diagnoses in France each year with five-year prevalence of approximately 65,000 cases, thus the opportunity to provide help throughout patient management process is significant, in France alone[4].
From a commercial perspective, France is just the beginning; the Volition team is actively discussing Nu.Q® Cancer, not only with hospital networks in other countries but also potentially licensing the technology to third party collaborators."Mr. Gael Forterre, Chief Commercial Officer, Volition concluded:"We are honored to have the support of our long term collaborator, Hospices Civils de Lyon. Reimbursement is the next step on the path to the first use of Nu.Q® in clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives.""Reimbursement will be a major milestone for Volition in the commercialization and licensing of Nu.Q® in the human cancer field. Once achieved, we anticipate the introduction into routine clinical use in France by the fourth quarter, 2026."About ReimbursementThe Innovative Procedures Outside the Nomenclature (RIHN-référentiel des actes innovants hors nomenclature) framework allows for the early and temporary support of innovative procedures. This support is contingent upon the collection of data to facilitate the subsequent evaluation of these procedures by the French National Authority for Health (HAS), with a view to their integration into standard practice. Established by the Direction General for Healthcare (DGOS) as part of the development of innovation in healthcare, the RIHN provides a long-term support mechanism for innovative medical biology and anatomical pathology. Between 2021 and 2025, the DGOS led a reform to revitalize the RIHN and refocus it on innovation.About Hospices Civils de Lyon (HCL)The Hospices Civils de Lyon (HCL) are partners of the IHU SEPSIS (ex-PROMETHEUS). They constitute France's second-largest university hospital system (CHU). As a leading public healthcare institution, HCL encompasses 13 hospitals across the Lyon metropolitan area, covering all medical and surgical specialties. With over 23,000 professionals, including 5,000 physicians, HCL carries out missions in patient care, education, and research, in close collaboration with Université Claude Bernard Lyon 1 and numerous research institutes. As key contributors to medical innovation and healthcare organization in France, HCL provides high-quality care accessible to all patients. These capabilities are supported by state-of-the-art infrastructures in microbiology, molecular biology, and precision medicine, as well as active participation in clinical research and national surveillance networks.About Volition Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.  The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.Media Enquiries:Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620Safe Harbor StatementStatements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.1. Grolleau E, et al. Circulating H3K27 Methylated Nucleosome Plasma Concentration: Synergistic Information with Circulating Tumor DNA Molecular Profiling. Biomolecules. 2023;13(8):1255. https://doi.org/10.3390/biom13081255
2. Couraud S, et al  Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG study. ELCC 2024 Poster
3. Marie Piecyk et al, "H3K27Me3-nucleosome is a strong prognostic biomarker in Non-Small Cell Lung Cancer: interim results from the analysis of up to 832 patients at baseline" Poster 395 ELCC 2025
4. Global Cancer Observatory 2022 (accessed Jan 20, 2026)



View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-the-preparation-of-reimbursement-submission-for-its-nuq-cancer-assays-302675011.htmlSOURCE VolitionRx Limited

Original: VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

.30 small pump 

VNRX........................................................p/m

After the Werfen announcement I had Google AI provide info on NETs and then drilled down into those results. It has been a remarkable journey into molecular biology. I think the first licensing agreement provides the perfect start to introduce their analytic technology to the NET community. This field is receiving a lot of attention and is a target rich environment as they say. It covers a wide range of diseases so not a one trick pony. I hope they have the resources to execute on growing demand. TWT. I know first hand the challenges associated with C19 testing.

Why is there an office in Henderson, NV? Guess I should ask IR.
I'm considering offering to ship Cam a package containing shave cream, a razor, neck tie & jacket. This You Tube video is not exactly what I'd like to see from the leadership.

VNRX........................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

Edison Spotlight report posted today, 7/2/25.
https://ir.volition.com/news-events/presentations-and-reports
Great to see this data being professionally circulated to the investment community.

VNRX......................................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

VNRX........................................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

VNRX....................https://stockcharts.com/h-sc/ui?s=VNRX&p=W&b=5&g=0&id=p86431144783

Google patent search provided the following three results:

EP3264090B12011-12-072022-05-18Belgian Volition SrlMethod for detecting nucleosome adducts

PL3213084T32014-10-292021-07-26Belgian Volition SprlMethod for the enrichment of circulating tumor dna

BR112022003546A22019-08-272022-05-17Belgian Volition SrlMethod of isolating circulating nucleosomes

From the VolitionRX website investor presentation: https://volition.com/volition-video/
I noted Lagoda Investment so looked at their positioning = 6.09M shares which has increased by 12% as of 9-30. Refer to: https://hedgefollow.com/funds/Lagoda+Investment+Management+LP.
Lagoda paid an average of $2.29 so it makes me feel better about my average of $0.76.
Looks to be the leader in epigenetics. Need to look at the IP landscape next.

215,000 shares traded on7/9/2024 at 11;25 @ $0.60. Lately its been 20,000 a day. I think somebody knows something is up. TWT.

VNRX under $2

BEWARE OF THE STOCK PUMPING CRIMINAL WHO SHORTS HIS OWN PUMPS!!!!!!!

CHECK OUT HIS POSTING HISTORY!!!!!!!